Clinical trials of resveratrol
Top Cited Papers
- 24 January 2011
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1215 (1), 161-169
- https://doi.org/10.1111/j.1749-6632.2010.05853.x
Abstract
This paper was published as Annals of The New York Academy of Sciences, 2011, 1215, pp. 161-169. It is available from www3.interscience.wiley.com. DOI: 10.1111/j.1749-6632.2010.05853.xMetadata only entryAn expanding body of preclinical evidence suggests resveratrol has the potential to impact a variety of human diseases. To translate encouraging experimental findings into human benefits, information is first needed on the safety, pharmacokinetics, pharmacodynamics, and, ultimately, clinical efficacy of resveratrol. Published clinical trials have largely focused on characterizing the pharmacokinetics and metabolism of resveratrol. Recent studies have also evaluated safety and potential mechanisms of activity following multiple dosing, and have found resveratrol to be safe and reasonably well-tolerated at doses of up to 5 g/day. However, the occurrence of mild to moderate side effects is likely to limit the doses employed in future trials to significantly less than this amount. This review describes the available clinical data, outlines how it supports the continuing development of resveratrol, and suggests what additional information is needed to increase the chances of success in future clinical trialsKeywords
This publication has 28 references indexed in Scilit:
- Steady-State Pharmacokinetics and Tolerability of Trans-Resveratrol 2000 mg Twice Daily with Food, Quercetin and Alcohol (Ethanol) in Healthy Human SubjectsClinical Pharmacokinetics, 2010
- Matrix effects on the bioavailability of resveratrol in humansFood Chemistry, 2010
- Quantification of free and protein‐bound trans‐resveratrol metabolites and identification of trans‐resveratrol‐C/O‐conjugated diglucuronides – Two novel resveratrol metabolites in human plasmaMolecular Nutrition & Food Research, 2008
- Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive AgentCancer Epidemiology, Biomarkers & Prevention, 2007
- Diagnostic Performance of Urinary Resveratrol Metabolites as a Biomarker of Moderate Wine ConsumptionClinical Chemistry, 2006
- Bioavailability oftrans-resveratrol from red wine in humansMolecular Nutrition & Food Research, 2005
- Uptake of Diet Resveratrol into the Human Low-Density Lipoprotein. Identification and Quantification of Resveratrol Metabolites by Liquid Chromatography Coupled with Tandem Mass SpectrometryAnalytical Chemistry, 2005
- HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANSDrug Metabolism and Disposition, 2004
- Urinary and Plasma Levels of Resveratrol and Quercetin in Humans, Mice, and Rats after Ingestion of Pure Compounds and Grape JuiceJournal of Agricultural and Food Chemistry, 2004
- Absorption of three wine-related polyphenols in three different matrices by healthy subjectsClinical Biochemistry, 2003